» Articles » PMID: 3025207

Agents That Elevate CAMP Levels in Platelets Decrease Thrombin Binding

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1987 Jan 5
PMID 3025207
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The effect of high intracellular levels of cAMP on the ability of rabbit and human platelets to bind and respond to thrombin was examined. Control rabbit platelets differed from human platelets in two interesting respects: they showed thrombin-dependent up-regulation of thrombin binding, but also a 3- to 5-fold lower thrombin-binding capacity. Nevertheless, treatment with prostaglandin E1 + theophylline or with forskolin decreased thrombin binding to both rabbit and human platelets by 60 to 70%. This effect was associated with a marked increase in the level of cAMP and seemed to depend on a decrease in number rather than affinity of thrombin-binding sites. Changes in thrombin binding correlated closely with changes in thrombin-stimulated incorporation of 32Pi into phosphatidic acid and a 40-kDa protein. However, regardless of the amount of thrombin that bound to treated platelets, thrombin-stimulated phosphorylation of a 20-kDa protein and serotonin secretion were severely inhibited. Thus, increased levels of platelet cAMP are associated with a reduced ability to bind and respond to thrombin. However, thrombin binding to platelets correlates more closely with some responses than others, presumably because cAMP inhibits additional platelet reactions.

Citing Articles

Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy.

Knowles R, Warner T Pharmacol Ther. 2018; 193:83-90.

PMID: 30081048 PMC: 6325790. DOI: 10.1016/j.pharmthera.2018.08.004.


Inhibition of platelet activation and thrombus formation by adenosine and inosine: studies on their relative contribution and molecular modeling.

Fuentes E, Pereira J, Mezzano D, Alarcon M, Caballero J, Palomo I PLoS One. 2014; 9(11):e112741.

PMID: 25393959 PMC: 4231063. DOI: 10.1371/journal.pone.0112741.


Suppression of platelet aggregation by Bordetella pertussis adenylate cyclase toxin.

Iwaki M, Kamachi K, Heveker N, Konda T Infect Immun. 1999; 67(6):2763-8.

PMID: 10338478 PMC: 96579. DOI: 10.1128/IAI.67.6.2763-2768.1999.


P1,P4-dithio-P2,P3-monochloromethylene diadenosine 5',5'''-P1,P4-tetraphosphate: a novel antiplatelet agent.

Chan S, Gallo S, Kim B, Guo M, Blackburn G, Zamecnik P Proc Natl Acad Sci U S A. 1997; 94(8):4034-9.

PMID: 9108100 PMC: 20563. DOI: 10.1073/pnas.94.8.4034.


Regulation of the receptor for platelet-activating factor on human platelets.

Burgers J, Akkerman J Biochem J. 1993; 291 ( Pt 1):157-61.

PMID: 8385926 PMC: 1132495. DOI: 10.1042/bj2910157.